readthroughSign in
CompanySMMTNasdaqMiami, FL

Summit Therapeutics

Summit Therapeutics develops ivonescimab, a bispecific antibody combining PD-1 blockade with anti-VEGF activity for oncology indications.

8-KNov 16Latest SEC filing
Nov 16Latest story

November 2026

October 2026

September 2026

August 2026

July 2026